Torrent Pharmaceuticals Ltd 2024 IR
The report highlights Torrent Pharmaceuticals Limited's performance for the fiscal year 2023-24, showcasing a 12% revenue growth and a 19% increase in Operating EBITDA. The company expanded its consumer healthcare segment and entered a strategic alliance with Zydus Lifesciences to co-market Saroglitazar. On the environmental front, the company achieved a 25.1% reduction in its carbon footprint and installed a 1.70 MW solar energy capacity. Additionally, Torrent Pharma successfully integrated its Curatio acquisition, strengthening its presence in the dermatology segment.
Company: Torrent Pharmaceuticals Ltd
Sector: Health Care
Country: India
Year: 2024
Type: IR
Pages: 404
Torrent Pharmaceuticals Ltd
Integrated Annual Report
The report highlights Torrent Pharmaceuticals Limited's performance for the fiscal year 2023-24, showcasing a 12% revenue growth and a 19% increase in Operating EBITDA. The company expanded its consumer healthcare segment and entered a strategic alliance with Zydus Lifesciences to co-market Saroglitazar. On the environmental front, the company achieved a 25.1% reduction in its carbon footprint and installed a 1.70 MW solar energy capacity. Additionally, Torrent Pharma successfully integrated its Curatio acquisition, strengthening its presence in the dermatology segment.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees